CHICAGO — Mark L. Moster, MD, of Wills Eye Hospital, discusses results of the REVERSE clinical trial, which is evaluating the efficacy of GS010 (GenSight Biologics) to treat Leber hereditary optic neuropathy, at the American Academy of Ophthalmology meeting.